Recombinant Mouse Flt3l, Fc tagged

• Cat.No.: Flt3l-8704M
• Product Overview: Recombinant Mouse Flt3l (P49772-1) (Met1- Arg188), fused with the Fc region of human IgG1 at the C-terminus, was produced in Human Cell.

Specification

• Species: Mouse
• Source: Human Cells
• Tag: Fc
• Protein Length: 1-188 a.a.
• Form: Lyophilized from a 0.2μm filtered solution of PBS, pH 7.4
• Molecular Mass: The recombinant mouse FLT3L /Fc is a disulfide-linked homodimer. The reduced monomer comprises 403 amino acids and has a predicted molecular mass of 45.4 kDa. The apparent molecular mass of the protein is approximately 56 and 35 kDa in SDS-PAGE under reducing conditions due to glycosylation.
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Stability: Samples are stable for up to twelve months from date of receipt at -70oC.
• Storage: Store it under sterile conditions at -20oC~-70oC. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution. Centrifuge the vial at 4℃ before opening to recover the entire contents.

Gene Information

• Gene Name: Flt3l FMS-like tyrosine kinase 3 ligand [ Mus musculus (house mouse) ]
• Official Symbol: Flt3l
• Gene ID: 14256
• mRNA Refseq: NM_013520
• Protein Refseq: NP_038548
• UniProt ID: P49772

Citation

A new cancer immunotherapy via simultaneous DC-mobilization and DC-targeted IDO gene silencing using an immune-stimulatory nanosystem.

Journal: International journal of cancer    PubMed ID: 29752722    Data: 2019/1/25

Authors: Yujuan Zhang, Jiamin Fu, Weiping Min

Article Snippet:Three days after tumor cell inoculation, the tumor-bearing mice were treated with PBS (control), man-GNR, PEI-GNR-siIDO, or man-GNR-siIDO (wt(PEI-GNR or man-GNR):wt(siRNA) = 400 μg:80μg) with 5-day intervals, until endpoint (day 22) of experiment.Three days after tumor cell inoculation, the tumor-bearing mice were treated with PBS (control), man-GNR, PEI-GNR-siIDO, or man-GNR-siIDO (wt(PEI-GNR or man-GNR):wt(siRNA) = 400 μg:80μg) with 5-day intervals, until endpoint (day 22) of experiment.. For the combination treatment, the last of group mice were treated with man-GNR-siIDO, as described above, along with i.v. injection of Flt3-L (Creative BioMart, US) (10 μg/day/mouse) for 8 consecutive days.. All the mice were sacrificed on day 22.All the mice were sacrificed on day 22.